Loading clinical trials...
Loading clinical trials...
Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Conditions
Interventions
Goserelin Acetate
Pembrolizumab
Locations
7
United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
University of Illinois Cancer Center
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Univeristy of Maryland
Baltimore, Maryland, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
University of Minnesota: Masonic Cancer Center
Minneapolis, Minnesota, United States
Start Date
May 30, 2019
Primary Completion Date
April 1, 2026
Completion Date
August 1, 2026
Last Updated
December 31, 2025
NCT04704661
NCT06805617
NCT05075980
NCT04895735
NCT05924256
NCT05669664
Lead Sponsor
Manish Patel
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions